Cerevel Therapeutics Holdings, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cerevel Therapeutics Holdings, Inc.
A week after bidding more than $10bn for ImmunoGen, AbbVie made one of 2023’s largest acquisitions again, this time betting big on Cerevel and its emraclidine for schizophrenia.
Public Company Edition: PTC sold more of its Evrysdi royalties to Royalty Pharma for $1bn. Abivax gained $235.8m in an IPO and concurrent private placement, while Cerevel grossed $450m and Nuvalent and Ultragenyx raised $300m each in follow-on offerings, but Freeline is reviewing strategic options.
Private Company Edition: Flare Therapeutics, targeting transcription factors to discover precision medicines, had big pharma backing for its second venture capital financing. Also, Mediar closed a $10m series A round, Switch launched with $52m and EpiBiologics raised a $50m series A round.
During Q3, biopharmas brought in an aggregate $18.1bn in financing and device company fundraising totaled $5.1bn; while in vitro diagnostic firms and research tools players raised $771m.
- Other Names / Subsidiaries
- Cerevel Therapeutics, LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.